Skip to main content
SpringerLink
Log in

The detection and evaluation of human tumor metastases

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

Many biochemical indices are purported to have clinical utility in the detection and management of neoplasia. Experience gained during the past decade tends to indicate their having a more important role in the detection and monitoring of metastases than of the primary lesion. From this present review of some of the commoner human tumours, it is concluded that such marker substances are important adjuncts in the management of germ cell and certain endocrine and endocrine-related tumours. The carcinoembryonic antigen (CEA) provides a marker for many gastrointestinal cancers, but there are no presently available subtances with clinical usefulness for either breast or lung neoplasms. Alternative approaches to the detection of metastases are also presented. The particular use of antibody probes at an immunohistochemical level has been claimed to be able to detect micrometastastic disease in bone marrow or tumour-related monoclonal antibody probes may have application to other cancers in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (256): 495–497, 1975.

    Google Scholar 

  2. Edwards PAW: Review article. Some properties and applications of monoclonal antibodies. Biochem J (200): 1–10, 1981.

    Google Scholar 

  3. Neville AM, Foster CS, Moshakis V, Gore M: Monoclonal antibodies and human tumour pathology. Hum Pathol (13): 1067–1081.

  4. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med (122): 467–481, 1965.

    Google Scholar 

  5. Thomson DMP, Krupey J, Freedman SO, Gold P: The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA (64): 161–167, 1969.

    Google Scholar 

  6. Chu TM, Reynoso G, Hansen HJ: Demonstration of carcinoembryonic antigen in normal human plasma. Nature, (238): 152–153, 1972.

    Google Scholar 

  7. Egan ML, Pritchard DG, Todd W, Go VLW: Isolation and immunochemical and chemical characterization of carcinoembryonic antigen-like substances in colon lavages of healthy individuals. Cancer Res (37): 2638–2643, 1977.

    Google Scholar 

  8. Shiveley JE, Todd CW, Go VLW, Egan ML: Aminoterminal sequence of a carcinoembryonic antigen-like glycoprotein isolated from the colonic lavages of health individuals. Cancer Res (38): 503–505, 1978.

    Google Scholar 

  9. Breborowicz J, Easty GC, Birbeck M, Robertson D, Nery R, Neville AM: The monolayer and organ culture of human colorectal carcinomata and the associated ‘normal’ colonic mucosa and their production of carcinoembryonic antigens. Br J Cancer (31): 559–569, 1975.

    Google Scholar 

  10. Neville AM, Laurence DJR: Report on the workshop of the carcinoembryonic antigen (CEA): the present position and proposals for future investigation. Int. J Cancer (14): 1–18, 1974.

    Google Scholar 

  11. Wagener C, Muller-Wallraf R, Nisson S, Groner J, Breuer H: Localization and concentration of carcinoembryonic antigen (CEA) in gastrointestinal tumours: correlation with CEA levels in plasma. J Natl Cancer Inst (67): 539–548, 1981.

    Google Scholar 

  12. Thomas P, Turberville C: Carcinoembryonic antigen in liver disease. Lancet (1): 833–834, 1979.

    Google Scholar 

  13. Sizaret PH, Esteve J: Relative potencies of four CEA preparations assayed by three commercial radioimmunoassay kits. J. Immunol Methods (34): 79–89, 1980.

    Google Scholar 

  14. Fritsche HA, Tashima CK, Collinsworth WL, Geitner A, VanOrt J: A direct competitive binding radioimmunoassay for carcinoembryonic antigen. J Immunol Methods (35): 115–128, 1980.

    Google Scholar 

  15. Tolnay GL, Oei TO, Mardis G, Heistand L: Experiences and opinions on CEA assay. Clin Chem (28): 1831, 1982.

    Google Scholar 

  16. Dierksheide WC: Official caution on CEA assay. Clin Chem (27): 507, 1981.

    Google Scholar 

  17. Accolla RS, Carrel S, Mach JP: Monoclonal antibodies specific for carcinoembryonic antigen and produced by 2 hybrid cell lines. Proc Natl Acad Sci USA (77): 563–568, 1980.

    Google Scholar 

  18. Rogers GT, Rawlins GA, Keep PA, Cooper EH, Bagshawe KD: Application of monoclonal antibodies to purified CEA in clinical radioimmunoassay of human serum. Br J Cancer (44): 371–380, 1981.

    Google Scholar 

  19. Buchegger F, Phan M, Rivier D, Carrel S, Accolla RS, Mach JP: Monoclonal antibodies against carcinoembryonic antigen (CEA) used in a solid-phase enzyme immunoassay. First clinical result. J. Immunol Methods (49): 129–140, 1982.

    Google Scholar 

  20. Pompecki R, Shively JE, Todd CW: Sera of cancer patients using a carcinoembryonic antigen-polyethylene glycol immunoassay. Cancer Res (14): 1910–1915, 1981.

    Google Scholar 

  21. Zamcheck MD: The present status of CEA in diagnosis, prognosis and evaluation of therapy. Cancer (36): 2460–2468, 1975.

    Google Scholar 

  22. Chu TM, Murphy GP. Carcinoembryonic antigen; Evaluation as screening assay in noncancer clinics. NY State J Med (78): 879–883, 1978.

    Google Scholar 

  23. Steele GJr, Ellenberg S, Ramming K, O'Connell M, Moertel C, Lessner H, Bruckner H, Horton J, Schein P, Zamcheck N, Novak J, Holyoke ED: CEA monitoring among patients in multi-institutional adjuvant GI therapy prococols. Ann Surg (196): 162–169, 1982.

    Google Scholar 

  24. Beatty JD, Romero C, Brown PW, Lawrence W, Terz JJ: Clinical value of carcinoembryonic antigen — Diagnosis, prognosis and follow up of patients with cancer. Arch Surg (114): 563–567, 1979.

    Google Scholar 

  25. LoGerfo P, Herter FP: Carcinoembryonic antigen and prognosis in patients with colon cancer. Ann Surg 181: 81–84, 1975.

    Google Scholar 

  26. Staab HJ, Anderer FA, Brummendorf T, Stumpf E, Fischer R: Prognostic value of preoperative serum CEA level compared to clinical staging. I. Colorectal carcinoma. Br J Cancer (44): 652–662, 1981.

    Google Scholar 

  27. Slater G, Papatestas AE, Aufes AHJr: Preoperative carcinoembryonic antigen levels in colorectal carcinoma. Arch Surg (114): 52–53, 1979.

    Google Scholar 

  28. Booth SN, Jamieson GC, King JPG, Leonard J, Oates GD, Dykes PW: Carcinoembryonic antigen in management of colorectal carcinoma. Br Med J (4): 183–187, 1974.

    Google Scholar 

  29. Valdivieso M, Mavligit GM: Chemotherapy and chemoimmunotherapy of colorectal cancer — role of carcinoembryonic antigen. Surg Clin North Amer (58): 619–632, 1978.

    Google Scholar 

  30. Neville AM, Patel S, Capp M, Laurence DJR, Cooper EH, Tuberville C, Coombes RC: Monitoring role of plasma CEA alone and in association with other tumour markers in colorectal and mammary carcinoma. Cancer (42): 1448–1451, 1978.

    Google Scholar 

  31. Goldenberg DM, Neville AM, Carter AC, Go VLW, Holyoke ED, Isselbacher KJ, Schein P, Lombardi VT, Schwartz M: Carcinoembryonic antigen: Its role as a marker in the management of cancer. Br Med J (282): 373–375, 1981.

    Google Scholar 

  32. Martin EWJr, James KK, Hurtubise PE, Catalano P, Minton JP: The use of CEA as an early indicator for gastrointestinal tumour recurrence and second-look procedures. Cancer (39): 440–446, 1977.

    Google Scholar 

  33. Wanebo HJ: Are carcinoembryonic antigen levels of value in the curative management of colorectal cancer? Surgery (89): 290–295, 1981.

    Google Scholar 

  34. Bell H, Orjasaeter H, Lange HF: Carcinoembryonic antigen (CEA) in patients with alcoholic liver diseases. Scan J Gastroenterol (14): 273–280, 1979.

    Google Scholar 

  35. Moertel CG, Schutt AJ, Go VLW: Carcinoembryonic antigen test for recurrent colortectal carcinoma. (239): 1065–1066, 1978.

    Google Scholar 

  36. Staab HJ, Anderer FA, Stumpf E, Fischer R: Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg (136): 322–327, 1978.

    Google Scholar 

  37. Martin EWJr, Cooperman M, Carey LC, Minton JP: Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res (28): 389–394, 1980.

    Google Scholar 

  38. Steele GJr, Zamcheck N, Wilson R, Mayer R, Lokich, Rau P, Maltz J: Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg (139): 544–549, 1980.

    Google Scholar 

  39. Cohen AM, Wood WC: Carcinoembryonic antigen levels as an indicator for reoperation in patients with carcinoma of the colon and rectum. Surg Gynecol Obstet (149): 22–26, 1979.

    Google Scholar 

  40. Wanebo HJ, Stearns M, Schwartz MK: Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer. Ann Surg (188): 481–493, 1978.

    Google Scholar 

  41. Evans JT, Mittelman A, Chu M, Holyoke ED: Preoperative and postoperative uses of CEA. Cancer (42): 1419–1421, 1978.

    Google Scholar 

  42. Moertel CG: Role of CEA — A challenge of a verdict. J Am Med Assoc (240): 1714–1715, 1978.

    Google Scholar 

  43. Lim CN-H, McPherson A, McClelland AR, McCoy L, Koch M: Value of serial CEA determinations in a surgical adjuvant trial of colorectal and gastric carcinoma. J Surg Oncol (14): 275–280.

  44. Attiyeh FF: Stearns MWJr: Second-look laparotomy based on CEA elevations in colorectal cancer. Cancer (47): 2119–2125, 1981.

    Google Scholar 

  45. Alsarraf M, Baker L, Talley RW, Kithier K, Vaitkevicius VK: Value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy — Southwest Oncology Group Study. Cancer (44): 1222–1225, 1979.

    Google Scholar 

  46. Lawton JO, Giles GR, Cooper EH: Evaluation of CEA in patients with known residual disease after resection of colonic cancer. J R Soc med (73): 23–28, 1980.

    Google Scholar 

  47. Shani A, O'Connell MJ, Moertel CG, Schutt AJ, Silvers A, Go VLW: Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med (88): 627–630, 1978.

    Google Scholar 

  48. Shochat D, Pant KD, Goldenberg DM: Colon-specific antigen-p (CSAp): II: further characterization in colorectal and pancreatic cancer. Cancer (50): 927–931, 1982.

    Google Scholar 

  49. Gazinger U, Deutsch: Serum sialyltransferase levels as a parameter in the diagnosis and follow-up of gastrointestinal tumors. Cancer Res (40): 1300–1304, 1980.

    Google Scholar 

  50. Podolsky DK, Weisner MM, Isselbacher KJ, Cohen AM: A cancer-associated galactosyltransferase isoenzyme. N Engl J Med (299): 703–705, 1978.

    Google Scholar 

  51. Chu CY-T, Lai LT-Y, Pokala HP: Value of plasma α-1-acid glycoprotein assay in the detection of human colorectal cancer: comparison with carcinoembryonic antigen. J Natl Cancer Inst (68): 75–80, 1982.

    Google Scholar 

  52. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H: Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (42): 4820–4823, 1982.

    Google Scholar 

  53. Kemeny MM, Sugarbaker PH, Smith TJ, Edwards BK, Shawker T, Vermess M, Jones EA: A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg (195): 163–167, 1982.

    Google Scholar 

  54. Aburano T, Tonami N, Hisada K: Radioimmunoassay for carcinoembryonic antigen as an adjunct to liver scan in the detection of liver metastases from digestive tract cancer. J Nucl Med (20): 232–235, 1979.

    Google Scholar 

  55. McCartney WH, Potter PB: Carcinoembryonic antigen assay — Adjunct to liver scanning in hepatic metastases detection. Cancer (42): 1457–1462, 1978.

    Google Scholar 

  56. Kim EE, Deland FH, Casper S, Corgan RL, Primus FJ, Goldenberg DM: Radioimmunodetection of colorectal cancer. Cancer (45): 1243–1247, 1980.

    Google Scholar 

  57. Mach J-P, Carrel S, Forni M, Ritschard J, Donath A, Alberto P: Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J med (303): 5–9, 1980.

    Google Scholar 

  58. Chu TM, Nemoto T: Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst (51): 1119–1122, 1973.

    Google Scholar 

  59. Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ, Wells SA: Evaluation of the carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer (42): 1512–1519, 1978.

    Google Scholar 

  60. Myers RE, Stutherland DJ, Meakin JW, Kellen JA, Malkin DG, Malkin A: Carcinoembryonic antigen in breast cancer. Cancer (42): 1520–1526, 1978.

    Google Scholar 

  61. Dell'ana B, Percudani M, Salvadori Cl: CEA and breast neoplasms: Application of a personal method for determination of CEA and breast neoplasms, Application of a personal method for determination of CEA in the clinical study of 242 patients (in French). Bull Cancer (66): 259–268, 1979.

    Google Scholar 

  62. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap H-W, Gutterman JU, Blumenschein GR: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (39): 1552–1562, 1979.

    Google Scholar 

  63. Bezwoda W, Derman D, Bothwell T, MacPhil P, Levin J, DeMoor N: Significance of serum concentrations of carcinoembryonic antigen, ferritin and calcitonin in breast cancer. Cancer (48): 1623–1628, 1981.

    Google Scholar 

  64. Coombes RC, Gazet J-C, Ford HT, Powles TJ, Nash AG, McKinna A, Neville AM: Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1): 296–297, 1980.

    Google Scholar 

  65. Steward AM, Nixon D, Zamcheck N, Aisenberg A: Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress. Cancer 33: 1246–1352, 1974.

    Google Scholar 

  66. Yap BS, Yap HY, Fritsche WA, Blumenschein G, Bodey GP: CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. J Am Med Assoc (244): 1601–1603, 1980.

    Google Scholar 

  67. Dearnaley DP, Patel S, Powles TJ, Coombes RC: Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer. Oncodev Biol Med (2): 305–311, 1981.

    Google Scholar 

  68. Cowen DM, Searle F, Ward AM, Benson EA, Smiddy FG, Eaves G, Cooper EH: Multivariate biochemical indicators of breast cancer evaluation of their potential in routine practice. Eur J Cancer (14): 885–894, 1978.

    Google Scholar 

  69. Cove DH, Woods KL, Smith SCH, Burnett D, Leonard J, Grieve RJ, Howell A: Tumor markers in breast cancer. Br J Cancer (40): 710–718, 1979.

    Google Scholar 

  70. Hall L, Craig RK, Davie MS, Ralphs DNL, Campbell PN: α-Lactalbumin is not a marker of human hormone-dependent breast cancer. Nature (290): 602–604, 1981.

    Google Scholar 

  71. Haagensen DEJr, Mazoukian G, Dilley WG, Pedersen CE, Kister SJ, Wells SAJr: Breast gross cystic disease fluid analysis. I. isolation and radioimmunoassay for a major component protein. J Natl Cancer Inst (62): 239–248, 1979.

    Google Scholar 

  72. Walker RA: Demonstration of carcinoembryonic antigen in human breast carcinomas by the immunoperoxidase technique. J Clin Pathol (33): 356–360, 1980.

    Google Scholar 

  73. Shousha S, Lyssiotis T, Godfrey VM, Scheuer PJ: Carcinoembryonic antigen in breast-cancer tissue: a useful prognostic indicator. Br. Med J (1): 77–79, 1979.

    Google Scholar 

  74. Smith SR, Howell A, Minawa A, Morrison JM: The clinical value of immunohistochemically demonstrable CEA in breast cancer: A possible method of selecting patients for adjuvant chemotherapy. Br J Cancer (46): 757–764, 1982.

    Google Scholar 

  75. Ceriani RL, Thompson K, Peterson JA, Abraham S: Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci (74): 582–586, 1977.

    Google Scholar 

  76. Ceriani RL, Sasaki M, Sussman H, Wara WM, Blank EW: Circulating human mammary epithelial antigens in breast cancer. Proc Natl Acad Sci (79): 5420–5424, 1982.

    Google Scholar 

  77. Heyderman E, Steele K, Ormerod MG: A new antigen on the epithelial membrane its immunoperoxidase localisation in normal and neoplastic tissue. J Clin Pathol (32): 35–39, 1979.

    Google Scholar 

  78. Dearnaley DP, Ormerod MG, Sloane JP, Lumley H, Imrie S, Jones M, Coombes RC, Neville AM: Detection of isolated mammary carcinoma cells in the marrow of patients with primary breast cancer. J R Soc Med (76): 359–364, 1983.

    Google Scholar 

  79. Foster CS, Dinsdale FA, Edwards PAW, Neville AM: Monoclonal antibodies to the human mammary gland. 2. Distribution of determinants in breast carcinomas. Virchows Arch (Pathol Anat) (394): 295–305, 1982.

    Google Scholar 

  80. Arklie J, Taylor-Papadimitriou J, Bodmer W, Egan W, Millis R: Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer (28): 23–30, 1981.

    Google Scholar 

  81. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF: Monoclonal antibodies to epitheliumspecific components of the human milk fat globule membrane — production and reaction with cells in culture. Int J Cancer (28): 17–22, 1981.

    Google Scholar 

  82. Foster CS, Edwards PAW, Dinsdale EA, Neville AM: Monoclonal antibodies to the human mammary gland. 1. Distribution of determinants in non-neoplastic mammary and extra mammary tissues. Virchows Arch (Pathol Anat) (394): 279–295, 1982.

    Google Scholar 

  83. Nuti M, Teramoto YA, Marianicostantini R, Hand PH, Colcher D, Schlom J: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer (29): 539–546, 1982.

    Google Scholar 

  84. Rasmussen BB, Hilkens J, Hilgers J, Nielsen HH, Thorpe SM, Rose C: Monoclonal antibodies applied to primary human breast status carcinoma: Relationship to menopausal status, lymph node status, and steroid hormone receptor content. Breast Cancer Res Treat (2): 401–405, 1982.

    Google Scholar 

  85. Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer: Lancet (1): 995–997, 1979.

    Google Scholar 

  86. Westerberg H, Gustafson SA, Nordenskjold B, Silfversward C, Wallgren A: Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer (26): 429–433. 1980.

    Google Scholar 

  87. Allegra JC, Lippman ME, Thompson EB, Simon R, Briock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: Association between steroid hormone receptors and response rate to cytoxic chemotherapy in metastatic breast cancer. Cancer Treat Rep (62): 1281–1286, 1978.

    Google Scholar 

  88. Hueson JC, Leclercq G, Andry G, Paridaens R, Legros N, Mattheiem WH, Sulvester R: Oestrogen receptors. In: Symington T, Williams AE, McVie JG (eds) Cancer assessment and monitoring, Churchill Livingston, Edinburgh, 1980, pp 344–356.

    Google Scholar 

  89. Silvestrini R, Daidone MG, Difronzo G: Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer (44): 665–670, 1979.

    Google Scholar 

  90. Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (38): 4292–4295, 1978.

    Google Scholar 

  91. Pichon M-F, Pallud C, Brunet M, Milgrom E: Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res (40): 3357–3360, 1980.

    Google Scholar 

  92. Campbell FC, Blamey RW, Elston CW, Nicholson RI, Griffiths K, Haybittle JL: Oestrogen-receptor status and sites of metastasis breast cancer. Br J Cancer (44): 456–459, 1981.

    Google Scholar 

  93. Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurent breast cancer. Eur J Cancer (17): 449–453, 1981.

    Google Scholar 

  94. Walt AJ, Singhakowinta A, Brooks SC, Cortez A: The surgical implication of estrophile protein estimations in carcinoma of the breast. Surgery (80): 506–512, 1976.

    Google Scholar 

  95. Singhakowinta A, Potter HG, Buroker TR, Samal B, Brooks SC, Vaitkevicius VK: Estrogen receptor and natural course of breast cancer. Ann Surg (183): 84–88, 1976.

    Google Scholar 

  96. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med (299): 1330–1335, 1978.

    Google Scholar 

  97. Hanhel R, Woodings R, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer (44): 671–675, 1979.

    Google Scholar 

  98. Chamness GC, Mercer WD, McGuirie WL: J Histochem Cytochem (28): 792–798, 1980.

    Google Scholar 

  99. Fisher B, Nurten G, Zheng S, Saffer EA: Fluoreceinted estrone binding by human and mouse breast cancer cells. Cancer Res (42): 540–549, 1982.

    Google Scholar 

  100. Barrows GH, Stroupe SB, Riehm JD: Nuclear uptake of a 17β-estradiol-fluorescein derivative as a marker of estrogen dependence. Am J Clin Pathol (73): 330–339, 1980.

    Google Scholar 

  101. Brennan MJ, Donegan WL, Appleby DE: The variability of estrogen receptors in metastatic breast cancer. Am J Surg (137): 260–262, 1979.

    Google Scholar 

  102. Leclercq G, Heuson JC, Deboel MC, Mattheiem WH: Oestrogen receptors in breast cancer; A changing concept. Br Med J (1): 185–189, 1975.

    Google Scholar 

  103. Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Haybittle JL: Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (2): 1317–1321, 1982.

    Google Scholar 

  104. Webster DJT, Bronn DG, Minton JP: Estrogen receptor levels in multiple biopsies from patients with breast cancer. Am J Surg (136): 337–338, 1978.

    Google Scholar 

  105. Hoehn JL, Plotka ED, Dickson KB: Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg (190): 69–71, 1979.

    Google Scholar 

  106. Lees H: Cellular estrogen and progesterone in mammary carcinoma. Am J Clin Pathol (73): 323–329, 1980.

    Google Scholar 

  107. Mairessse M, Devleeschouwer N, Leclerq G, Galand P: Estrogen-induced protein in the human breast cancer cell line MCF—7. Biochem Biophus Res Commun (97): 1251–1257, 1980.

    Google Scholar 

  108. Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL: Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells. Cancer Res (43): 1204–1210, 1983.

    Google Scholar 

  109. Browne P, Bagshawe KD: Enhancement of human chorionic gonadotrophin production by antimetabolites. Br J Cancer (146): 22–29, 1982.

    Google Scholar 

  110. Borkowski A, Muquardt C: Human chorionic gonadotrophin in the plasma of normal, nonpregnant subjects. N Engl J Med (301): 298–302, 1979.

    Google Scholar 

  111. Braunstein GD, Kamdar V, Rasor J, Swaminathan N, Wade ME: Widespread distribution of a chorionic gonadorophin-like substance in normal human tissues. J. Clin Endocrinol Metab (49): 917–925, 1979.

    Google Scholar 

  112. Yoshimoto Y, Wolfsen AR, Hirose F, Odell WD: Human chorionic gonadotrophin-like material: Presence in normal human tissues. Am J Obstet Gynecol (134): 729–733, 1979.

    Google Scholar 

  113. Hatch KD, Shingleton HM, Younger B, Boots LR: Elevated titers of the beta subunit of human chorionic gonadotrophin in oophorectimized women being treated for trophoblastic disease. Am J Obstet Gynecol (137): 122–128, 1980.

    Google Scholar 

  114. Javadpour N, Chen H-C: Improved human chorionic gonadotrophin detection with carboxyl-terminal radioimmuno-assay of the beta subunit on concentrated 24-hour urine in patients with testicular cancer. J. Urol (126): 176–178, 1981.

    Google Scholar 

  115. Surwit EA, Hammond CB: Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol (55): 565–570, 1980.

    Google Scholar 

  116. McComb P, Yuen BH, Boyes D, White G: Recurrence of metastatic trophoblastic disease after negative plasma human chorionic gonadotrophin β-subunit assay. Gynecol Oncol (9): 114–116, 1980.

    Google Scholar 

  117. Vaughn TC, Surwit EA, Hammond CB: Late recurrence of gestational trophoblastic neoplasia. Am J Obstet Gynecol (138): 73–76, 1980.

    Google Scholar 

  118. O'Brien TJ, Engvall E, Schlaerth JB, Morrow CP: Trophoblastic disease monitoring — Evaluation of pregnancy-specific beta-1-glycoprotein. Am J Obstet Gynecol (138): 313–320, 1980.

    Google Scholar 

  119. Bagshawe KD, Harland S: Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer 38: 112–118, 1976.

    Google Scholar 

  120. Berkowitz RS, Osathanondh R, Golstein DP, Martin PM, Mallampati SR, Datta S: Cerebrospinal fluid human chorionic gonadotrophin levels in normal pregnancy and choriocarcinoma. Surg Gynecol Obstet (153): 687–689, 1981.

    Google Scholar 

  121. Malwas C, Buffe D, Schweisguth O, Burtin P: α1 Foetoprotein and children's cancer. Rev. Eur Etudes Clin Biol (16): 430–435, 1971.

    Google Scholar 

  122. Alpert E: Alpha-1-fetoprotein: Serologic marker of human hepatcma and embryonal carcinoma. Natl Cancer Inst Monogr (35): 415–420, 1972.

    Google Scholar 

  123. Mostofi FK: Pathology of germ cell tumors of testis: A progress report. Cancer (45): 1735–1744, 1980.

    Google Scholar 

  124. Beilby JOW, Horne CHW, Milne GD, Parkinson C: Alphafetoprotein, alpha-1-antitrypsin and transferrin in gonadal yolk sac tumours. J Clin Pathol (32): 455–461, 1979.

    Google Scholar 

  125. Javadpour N, McIntire KR, Waldman TA: Human chorionic gonadotrophin (HCG) and alphafetoprotein (AFP) in sera and tumour cells of patients with testicular seminoma — Prospective study. Cancer 42: 2768–2722, 1978.

    Google Scholar 

  126. Javadpour N, Tumor markers aid therapy of testicular cancer. J Am Med Assoc (242):320–321, 1979.

    Google Scholar 

  127. Raghavan D, Heyderman D, Monaghan P, Gibbs J, Ruoslahti E, Peckham MJ, Neville AM: Hypothesis: When is a seminoma not a seminoma? J Clin Pathol (24): 123–128, 1981.

    Google Scholar 

  128. Germalluch JR, Begent RHJ, Bagshawe KD: Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer (42): 850–855, 1980.

    Google Scholar 

  129. Horn F, Hedinger C, Grob PJ: α1-fetoprotein and testicular tumours. Schweiz Med Wochenschr (110): 642–647, 1980.

    Google Scholar 

  130. Talerman A, Haije WG, Baggerman L: Serum alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: Correlation between endodormal sinus (yolk sac) tumour and raised serum AFP. Cancer (46): 380–385, 1980.

    Google Scholar 

  131. Talerman A: Yolk sac tumor associated with seminoma of the testis in adults. Cancer (33): 1468–1473, 1974.

    Google Scholar 

  132. Lange PH, Nochomovitz LE, Rosai J, Fraley EE, Kennedy BJ, Bosl G, Brisbane J, Catalona WJ, Cochran JS, Comisarow RH, Cummings KB, deKernion JB, Einhorn LH, Hakala TR, Jewett M, Moore MR, Scardino PT, Streitz JM: Serum alpha-fetoprotein and human chorionie gonadotrophin in patients with seminoma. J. Urol (124): 472–478, 1980.

    Google Scholar 

  133. Raghavan D, sullivan AL, Peckham MJ, Neville AM: Elevated serum alphafetoprotein and seminoma: Clinical evidence for a histologic continuum? Cancer (50):982–989, 1982.

    Google Scholar 

  134. Skinner DG, Scardino PT: Relevance of biochemical tumor markers and lymphadenectomy in management of nonseminomatous testis tumors: Current perspective. J. Urol (123): 378–382, 1980.

    Google Scholar 

  135. Scardino PT, Skinner DG: Germ cell tumors of the testis-Improved results in a prospective study using combined modality therapy and biochemical tumor markers. Surgery (86):86–93, 1979.

    Google Scholar 

  136. Kohn J: The value of apparent half-life assay of alpha-1 fetoprotein in the management of testicular teratoma In: Lehmann FG (ed) Carcino-embryonic proteins, vol II. Elsevier/North-Holland Biomedical Press, Amsterdam, 1979.

    Google Scholar 

  137. Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ: Acute changes of α-fetoprotein and human chorionic gonadotrophin during induction chemotherapy of cerm cell tumors. Cancer Res (42):4855–4861, 1982.

    Google Scholar 

  138. Artz K: Embryonal carcinoma antigens: Biologic and clinical implications. Semin Oncol (6): 53–54, 1979.

    Google Scholar 

  139. Schultz H, Sell A, Nøorgaard-Pedersen B, Arends J: Serum alpha-fetoprotein and human chorionic gonadotrophin as markers for the effect of postoperative radiation therapy and/or chemotherapy in testicular cancer. Cancer (42): 2182–2186, 1978.

    Google Scholar 

  140. Kohn J, Orr AH, McElwain TJ, Bentall M, Peckham MJ: Serum-alpha1-fetoprotein in patients with testicular tumours. Lancet (2):433–436, 1976.

    Google Scholar 

  141. Fowler JEjr, Platoff GE, Kubrock CA, Stutzman RE: Commercial radioimmunoassay for beta subunit of a human chorionic gonadotropin, Falsely positive determinations due to elevated serum luteinizing hormone. Cancer (49): 136–139, 1982.

    Google Scholar 

  142. Braunstein GD, McIntire KR, Waldmann TA: Discordance of human chorionic gonadotropin and alpha-fetoprotein in testicular teratocarcinomas. Cancer (31):1065–1068, 1973.

    Google Scholar 

  143. Perlin E, Engeler JE, Edson M, Karp D, McIntire KR, Waldmann TA: The vaule of serial measurement of both human chorionic gonadotrophin and alphafetoprotein for monitoring germinal cell tumours. Cancer (37): 215–219, 1976.

    Google Scholar 

  144. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in dissemination testicular cancer following chemotherapeutic cytoreduction. Cancer (48): 904–908, 1981.

    Google Scholar 

  145. Lange PH, Bremner RD, Horne CH, Vessela RL, Fraley EE: Is SP-1 a marker for testicular cancer? Urology (15): 251–255, 1980.

    Google Scholar 

  146. Narayana AS, Loening S, Weimar G, Culp DA: Serum markers in testicular tumors. J. Urol (121):51–53, 1979.

    Google Scholar 

  147. von Eyben FE: Lactic Dehydrogenase and its isoenzymes in testicular germ cell tumours: An overview. Oncodev Biol Med (in press).

  148. Kalser MH, Barkin JS, Redlhammer D,Heal A: Circulating carcinoembryonic antigen in pancreatic carcinoma. Cancer (42): 1468–1471, 1978.

    Google Scholar 

  149. Dilawari JB, Philippakos D, Blendis LM, Waller SL: Carcinomaembryonic antigen in differential diagnosis of carcinoma of pancrease from chronopancreatitis. Br Med J (2): 668, 1975.

    Google Scholar 

  150. Delwiche R, Zamcheck N, Marcon N: Carcinoembryonic antigen in pancreatitis. Cancer (31): 328–330, 1973.

    Google Scholar 

  151. Fitzgerald PJ, Fortner JG, Watson RC, Schwartz MK, Sherlock P, Benua RS, Cubilla AL, Schottenfeld D, Miller D, Winawer SJ, Lightdale CJ, Leidner SD, Nisselbaum JS, Menendezbotet CJ, Poleski MH: Value of diagnostic aids in detecting pancreas cander. Cancer (41): 868–879, 1978.

    Google Scholar 

  152. Neville AM: THe diagnostic value of plasma carcinoembryonic antigen (CEA) in pancreatic disease. Br J Cancer (41): 976–979, 1989.

    Google Scholar 

  153. Zamcheck N, Martin EW: Factors in controlling the circulating CEA levels in pancreatic cancer. Cancer (47): 1621–1627, 1980.

    Google Scholar 

  154. Barkin JS, Kalser MH, Kaplan R, Redlhammer D, Heal A: Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery, chemotherapy and radiation therapy. Cancer (42): 1472–1476, 1978.

    Google Scholar 

  155. Hobbs JR, Knapp ML, Branfoot AC: Pancreatic oncofoetal antigen (POA): Its frequency and localisation in humans. Oncodev Biol Med (1): 37–48, 1980.

    Google Scholar 

  156. Gelder F, Reese C, Moossa AR, Hunter R: Studies on oncofetal antigen PAO. Cancer (42): 1635–1645, 1978.

    Google Scholar 

  157. Gelder FB, Reese CJ, Moossa AR, Hall T, Hunter R: Purification, partial characterization, and clinical evaluation of a pancreatic oncofetal antigen. Cancer Res (38): 313–324, 1978.

    Google Scholar 

  158. Peterson LM: Serum RNase in the diagnosis of pancreatic carcinoma. Proc. Natl Acad Sci USA (76): 2630–2634, 1979.

    Google Scholar 

  159. Doran G, Allen_Mersh TG, Reynolds KW. Ribonuclease as a tumour marker for pancreatic carcinoma. J Clin Pathol (33): 1212–1213, 1980.

    Google Scholar 

  160. Ruddell WSJ, Mitchell CJ, Hamilton I, Leek JP, Kelleher J: clinical value of serum immunoreactive trypsin concentration. Br Med J (283): 1429–1432, 1981.

    Google Scholar 

  161. Broder LE, Carter SK Pancreatic islet cell carcinoma. Ann Intern Med (79): 101–107, 1973.

    Google Scholar 

  162. Marks V: Progress report. Diagnosis of insulinoma. Gut (12): 835–843, 1971.

    Google Scholar 

  163. Daggett PR, Goodburn EA, Kurtz AB, LeQuesnc LP, Morris DV, Nabarro JDN, Raphael MJ: Is preoperative localization of insulinomas necessary? Lancet (1): 483–486, 1981.

    Google Scholar 

  164. Galbut DL, Markowitz AM: Insulinoma: Diagnosis surgical management and long-term follow-up. Review of 41 cases. Am J Surg (138): 682–690, 1980.

    Google Scholar 

  165. Deveney CW, Deveney KS, Way LW: Zollinger-Ellison syndrome-23 years later. Ann Surgery (188): 384–393, 1978.

    Google Scholar 

  166. Stage JG, Stadil JF, Rehfeld JF, Fahrenkrug J, Schaffalitzkydemuckadell OB: Secretion and Zollinger-Ellison syndrome—Reliability of secretin tests and pathogenic role of secretin. Scand J Gastroenterol (13): 500–511, 1978.

    Google Scholar 

  167. Stage JG, Stadil F: The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol [Suppl] (14): 79–91, 1979.

    Google Scholar 

  168. Stabile BE, Braunstein GD, Passaro E: Serum gastrin and human chorionic gonadotrophin in the Zollinger-Ellison syndrome. Arch Surg (115):1090–1094, 1980.

    Google Scholar 

  169. Bonfils S, Mignon M, Landor JH: Management of Zollinger-Ellison syndrome. N Engl J Med (303): 942, 1980.

    Google Scholar 

  170. McCarthy DM: Current concepts: The place of surgery in the Zollinger-Ellison syndrome. N Eng J Med (302): 1344–1347, 1980.

    Google Scholar 

  171. Wilson SD: The role of surgery in children with the Zollinger-Ellison syndrome. Surgery (92): 682–692, 1982.

    Google Scholar 

  172. Barreras RF, Mack E, Goodfriend T, Damm M: Resection of gastrinoma in the zollinger-Ellison syndrome. Gastroenterology (82): 953–956, 1982.

    Google Scholar 

  173. zollinger RM, Ellison EC, Fabri PJ, Johnson J, Sparks J, Carey LC: Primary peptic ulcerations of the jejunum associated with islet cell tumors — 25 year appraisal. Ann Surg (192): 422–432, 1980.

    Google Scholar 

  174. Heath HIII, Sizemore GW: Radioimmunoassay for calcitonin. Clin Chem (28): 1219–1226, 1982.

    Google Scholar 

  175. Graze K, Spiler IJ, Tashjian AHJr, Melvin EW, Cervic-Skinner S, Gagel RF, Miller HH, Wolfe HJ, DeLellis RA, Leape L, Feldman ZT, Reichlin S: Natural history of familial medullary thyroid carcinoma. N Engl J Med (299): 980–985, 1978.

    Google Scholar 

  176. Starling JR, Harris C, Granner DK: Diagnosis of occult familial medullary carcinoma of thyroid using pentagastrin. Arch Surg (113): 241–244, 1978.

    Google Scholar 

  177. Fletcher DR, Medullary carcinoma of thyroid and phaeo-chromocytoma. J R Soc med (71): 289–291, 1978.

    Google Scholar 

  178. Carney JA, Sizemore GW, Hayles AB: C-cell disease of the thyroid gland in multiple endocrine neoplasia, type 2b. Cancer (44): 2173–2183, 1979.

    Google Scholar 

  179. DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AMJr, Wolfe HJ: Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma. Am J Clin Pathol (70): 587–594, 1978.

    Google Scholar 

  180. Trump DL, Mendelsohn G, Baylin SB: Discordance between plasma calcitonin and tumor-cell mass in medullary thyroid carcinoma. N Engl J Med (301): 253–255, 1979.

    Google Scholar 

  181. Lippman SM, Mendelsohn G, Trump DL, Wells SA, Baylin SB: The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma — A study of calcitonin, L-DOPA decarboxylase and histaminase. J Clin Endocrinol Metab (54): 233–240, 1982.

    Google Scholar 

  182. Becker KL, Silva OL, Snider RH, Moore CF, Geelhoed GW: The surgical implications of hypercalcitonemia. Surg Gynecol Obstet (154): 897–908, 1982.

    Google Scholar 

  183. Stepanas AV, Samaan NA, Hill CS, Hickey RC: Medullary thyroid carcinoma — Importance of serial serum calcitonin measurement. Cancer (43): 825–837, 1979.

    Google Scholar 

  184. Jackson CE, Tashjian AHJr, Block MA: Detection of medullary thyroid cancer by calcitonin assay in families. Ann Intern Med (78): 845–872, 1973.

    Google Scholar 

  185. Ulbright TM, Kraus FT, O'Neal LW: C-cell hyperplasia developing in residual thyroid following resection for sporadic medullary carcinoma. Cancer (48): 2076–2079, 1981.

    Google Scholar 

  186. Jackson CE, Greenwald KA, Yott JB, Tashjian AH: Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg (115): 142–151, 1980.

    Google Scholar 

  187. Norton JA, Doppman JL, Brennan MF: Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Am J Surg Pathol (4): 277–280, 1980.

    Google Scholar 

  188. Baylin SB, Beaven MA, Keiser HR, Tashjian ANJr, Melvine KEW: Serum histaminase and calcitonin levels in medullary carcinoma of the thyroid. Lancet (1): 455, 458, 1972.

    Google Scholar 

  189. Schmechel D, Marangos PJ, Brightman M, Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. (Nature (276): 834–836, 1978.

    Google Scholar 

  190. Tapia FJ, Polak JM, Barbosa AJA, Bloom SR, Marangos JP, Dermody C, Pearse AGE: Neuron-specific enolase is produced by neuroendocrine tumours. Lancet (1): 808–811, 1981.

    Google Scholar 

  191. Allannic H, Lorcy Y, Cornec A, LeMarc B, Calmettes C: Medullary carcinoma of the thyroid (MCT) study of a kindred. Ann Endocrinol (Paris) (41): 31–42, 1980.

    Google Scholar 

  192. Ishikawa N, Hamada S: Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer (34): 111–115, 1976.

    Google Scholar 

  193. Doyle TJ: Brain metastasis in the natural history of small-cell lung cancer. Cancer (50): 752–754, 1982.

    Google Scholar 

  194. Chapman GS, Kumar D, Redmond JIII, Gandara DR: Upper abdominal CT scanning in staging non-oat-cell lung carcinoma. N Engl J Med (307): 189, 1982.

    Google Scholar 

  195. Pollard EB, Tio F, Myers JW, Clark G, Coltman CAJr, VonHoff DD: Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung. Cancer Res (41): 1015–1020, 1981.

    Google Scholar 

  196. Minna JD, Bunn PAJr, Carney DN, Cohen MH, Cuttita F, Fossieck BEJr, Gazdar AF, Ihde DC, Johnston-Early A, Matthews MJ, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E: Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bull Cancer (69): 81–93, 1982.

    Google Scholar 

  197. Ham J. Williams JC, Ellison ML: Radioreceptor assay for the detection of biologically active forms of calcitonin. J Endocrinol (81): 152, 1979.

    Google Scholar 

  198. Ross EJ: Some clinical aspects of the para-endocrine syndromes. Proc R Soc Med (65): 59–60, 1972.

    Google Scholar 

  199. vincent RG, Chu TM, Lane WW: Value of carcinoembryonic antigen in patients with carcinoma in the lung. Cancer (44): 685–691, 1979.

    Google Scholar 

  200. Ford CHJ, Stokes HJ, Newman CE: Carcinoembryonic antigen and prognosis after radical surgery for lung cancer — Immunocytochemical localization and serum levels. Br J Cancer (44): 145–153, 1981.

    Google Scholar 

  201. Lokich JJ: Plasma CEA levels in small cell lung cancer: Correlation with stage, distribution of metastases and survival. Cancer (50): 215–2156, 1982.

    Google Scholar 

  202. Vincent RG, Chu TM, Fergen TB, Ostrander M: Carcinoembryonic antigen in 228 pagients with carcinoma of the lung. Cancer (36): 2069–2076, 1975.

    Google Scholar 

  203. Dent PB, McCulloch PB, Wesley James O, Mclaren R, Muirehead W, Dunnett CW: Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma. Cancer (42): 1484–1491, 1978.

    Google Scholar 

  204. Wang N, Huang S, Gold P: Absence of carcinoembryonic antigen-like materials in mesothelioma — Immunohistochemical differentiation from other lung cancers. Cancer (44): 937–943, 1979.

    Google Scholar 

  205. Vincent RG, Chu TM, Lane WW, Gutierrez AC, Stegemann PJ, Madajewicz S: Carcinoembryonic antigen as a monitor of successful surgical resection in 130 patients with carcinoma of the lung. J. Thorac Cardiovasc Surg (75): 734–739, 1978.

    Google Scholar 

  206. Ahlemann LH, Staab HJ, Koch HL, Anderer FA: Carcinoembryonic antigen (CEA) measurement as an aid to management of patients with lung cancer treated by radiotherapy. Oncodev Biol Med (1): 143–150, 1980.

    Google Scholar 

  207. Gennings JN, Bagshawe KD, Axelsen NH, Sizaret P: Collaborative study on bronchial tumour-associated antigens. Br J Cancer (44): 487–495, 1981.

    Google Scholar 

  208. Cuttita F, Rosen S, Gazdar AF, Minna JD: Monoclonal antibodies that demonstrate specificity for several types of human lung cancer. Proc Natl Acad Sci USA (78): 4591–4595, 1981.

    Google Scholar 

  209. Hanson M, Rehfeld JF, Stadil F: Small cell carcinoma of the lung: Relation of calcitonin to bone marrow metastases, parathromone and gastrin. Acta Med Scand (206): 215–218, 1979.

    Google Scholar 

  210. Roos BA, Lindall AW, Baylin SB, O'Neil JA, Frelinger AL, Birnbaum RS, Lambert PW: Plasma immunoreactive calcitonin in lung cancer. J. Clin Endocrinol Metab (50): 659–666. 1980.

    Google Scholar 

  211. Krauss S, Macy S, Ichiki AT: A study of immunoreactive calcitonin (CT) adrenocorticotropic hormone ACTH) and carcinoembryonic antigen (CEA) in lung cancer and other malignancies. Cancer (47): 2485–2492, 1981.

    Google Scholar 

  212. Hansen M, Hammer M, Hummer L: ACTH, ADH, and calcitonin concentrations as markers of response and relapse in small-cell carcinoma of the lung. Cancer (46): 2062–2067, 1980.

    Google Scholar 

  213. Broder LE, Doppman JL, Snider RH, Moore CF, Cohen MH, Becker KL: Calcitonin as a marker for bronchogenic cancer. Prospective study. Cancer (44): 680–684, 1979.

    Google Scholar 

  214. Carney DN, Marangos PJ, Idde DC, Bunn PAJr, Cohen MH, Minna JD: Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1): 583–585, 1982.

    Google Scholar 

  215. Baylin SB, Weisburger WR, Eggleston JC, Mendelsohn G, Beaven MA, Abeloff MD, Ettinger DS: Variable content of histaminase, L-DOPA dacorboxylase and calcitonin in small cell carcinoma of the lung. N Engl J Med (299): 105–110, 1978.

    Google Scholar 

  216. Woodward HQ: The clinical significance of serum acid phosphatase. Am J Med (27): 902–910, 1959.

    Google Scholar 

  217. Early diagnosis of carcinoma of the prostate. Editorial. Br Med J (1): 1036–1037, 1980.

  218. Mobley TL, Frank IN: Influence of tumor grade on survival and on serum acid phosphatase levels in metastatic carcinoma of the prostate. J Urol (99): 321–323, 1968.

    Google Scholar 

  219. Foti AG, Cooper JF, Herschman H, Sapon SR: Detection of prostatic cancer by radioimmunoassay—Review. Hum Pathol (9): 219, 1978.

    Google Scholar 

  220. Goldenberg SL, Silver HKB, Sullivan LD, Morse MJ, Archibald L: A critical evaluation of a specific radioimmunoassay for prostatic acid phosphatase. Cancer (50): 1847–1851, 1982.

    Google Scholar 

  221. Lindholm GR, Stirton MS, Liedtke J, Batjer JD: Prostatic acid phosphatase by radioimmunoassay. Sensitivity compared with enzymatic assay. J Am Med Assoc (244): 2071–2073, 1980.

    Google Scholar 

  222. Pontes JE, Choe BK, Rose NR, Pierce JMJr: Bone marrow acid phosphatase in staging of prostatic cancer: How reliable is it? J Urol (119): 772–776, 1978.

    Google Scholar 

  223. Belville WD, Cox HD, Mahan DE, Stutzman RE, Bruce AW: Prostatic acid phosphatase by radioimmunoassay tumor marker in bone marrow. J Urol (121): 442–446, 1979.

    Google Scholar 

  224. Jobis AC, DeVries GP, Anholt RRH, Sanders GTB: Demonstration of prostatic origin of metastases. Cancer (41): 1788–1793, 1978.

    Google Scholar 

  225. Naritoku WY, Taylor CR: A comparative study of the use of monoclonal antibodies using three different immunohistochemical methods: An evaluation of monoclonal and polyclonal antibodies against human prostatic acid phosphatase. J. Histochem Cytochem (30): 253–260, 1982.

    Google Scholar 

  226. Leathem A, Dinsdale E: Acid phosphatase as marker for carcinoma of prostate. Lancet (1): 1029, 1979.

    Google Scholar 

  227. Kuriyama M, Wang M, Papsidero LD, Kilian CS, Shimano T, Valenzuela L, Nishura T, Murphy GP, Chu TM: Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res (40): 4658–4662, 1980.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK

    D. J. R. Laurence & A. M. Neville

Authors
  1. D. J. R. Laurence
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. M. Neville
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laurence, D.J.R., Neville, A.M. The detection and evaluation of human tumor metastases. Cancer Metast Rev 2, 351–374 (1983). https://doi.org/10.1007/BF00048567

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00048567

Keywords

Search

Navigation